Your browser doesn't support javascript.
loading
: 20 | 50 | 100
1 - 20 de 277
4.
Pediatr Dermatol ; 40(4): 655-656, 2023.
Article En | MEDLINE | ID: mdl-37283451

Data regarding the treatment of childhood granulomatous periorificial dermatitis (CGPD) using oral therapies are limited. This study included 31 Chinese children with CGPD treated with oral roxithromycin. After 12 weeks of treatment, 90.3% of the patients recovered, and there were no severe adverse effects. Our results suggest that oral roxithromycin is an effective and safe treatment for CGPD.


Dermatitis, Perioral , Oral Ulcer , Roxithromycin , Child , Humans , Dermatitis, Perioral/drug therapy , East Asian People , Granuloma , Oral Ulcer/drug therapy , Roxithromycin/therapeutic use
5.
Vet Dermatol ; 34(5): 478-482, 2023 Oct.
Article En | MEDLINE | ID: mdl-37221446

Canine periocular dermatitis may be associated with excessive facial folds and heavy brows (EFF-HB). There is no gold standard therapy for EFF-HB-associated periocular dermatitis, and conventional medical management may fail. Herein, we describe periocular fluorescence photobiomodulation and rhytidectomy as novel approaches to treat EFF-HB-associated periocular dermatitis refractory to medical management.


La dermatite périoculaire canine peut être associée à des plis faciaux prononcés et à des sourcils épais (EFF-HB). Il n'y a pas de traitement de référence de la dermatite périoculaire associée à l'EFF-HB, et la prise en charge médicale conventionnelle peut échouer. Ici, nous décrivons la photobiomodulation par fluorescence périoculaire et la rhytidectomie comme de nouvelles approches pour traiter la dermatite périoculaire associée à l'EFF-HB réfractaire à la prise en charge médicale.


La dermatitis periocular canina puede estar asociada con pliegues faciales excesivos y cejas densas (EFF-HB). No existe una terapia estándar para la dermatitis periocular asociada a EFF-HB, y el tratamiento médico convencional puede fallar. En este artículo describimos el uso de fotobiomodulación periocular de fluorescencia y ritidectomía como nuevas terapias para tratar la dermatitis periocular asociada a EFF-HB refractaria al tratamiento médico habitual.


A dermatite periocular canina pode estar associada a dobras faciais excessivas e sobrancelhas pesadas (EFF-HB). Não há nenhuma terapia de padrão ouro para dermatite periocular associada a EFF-HB, e os tratamentos clínicos convencionais podem falhar. Neste trabalho, nós descrevemos a fotobiomodulação fluorescente periocular e a retidectomia como novas abordagens para o tratamento de dermatite periocular associada a EFF-HB refratária ao tratamento medicamentoso.


Dermatitis, Perioral , Dog Diseases , Rhytidoplasty , Animals , Dogs , Dermatitis, Perioral/veterinary , Rhytidoplasty/veterinary , Fluorescence , Dog Diseases/radiotherapy , Dog Diseases/surgery
8.
J Vet Sci ; 24(1): e6, 2023 Jan.
Article En | MEDLINE | ID: mdl-36560838

Two Shih-Tzu dogs with atopic dermatitis presented with delayed periocular dermatitis (PD) following the instillation of dorzolamide and dorzolamide/timolol combination eyedrops; the development of dermatologic signs took 94 and 104 d in cases 1 and 2, respectively. Hypersensitivity to anti-glaucoma eyedrops was highly suspected, and treatment was discontinued. Delayed PD was significantly relieved in cases 1 and 2, at days 155 and 64 after discontinuation, respectively. In this study, the clinical characteristics and progression of delayed PD were described to inform clinicians who may encounter this rare side effect.


Dermatitis, Atopic , Dermatitis, Perioral , Dog Diseases , Glaucoma , Dogs , Animals , Ophthalmic Solutions/therapeutic use , Dermatitis, Atopic/drug therapy , Dermatitis, Atopic/veterinary , Dermatitis, Perioral/veterinary , Glaucoma/drug therapy , Glaucoma/veterinary , Dog Diseases/chemically induced , Dog Diseases/drug therapy
12.
Clin Exp Dermatol ; 47(8): 1605-1608, 2022 Aug.
Article En | MEDLINE | ID: mdl-35580890

This is the case of an infant with a persistent dermatitis affecting the perioral, acral and napkin areas, in whom a simple oral therapy provided a rapid treatment response.


Dermatitis, Perioral , Dermatitis , Dermatitis/diagnosis , Humans , Infant
13.
J Dtsch Dermatol Ges ; 20(2): 185-202, 2022 Feb.
Article En | MEDLINE | ID: mdl-35088524

The influence of nutrition on the pathophysiology and clinical severity of inflammatory facial dermatoses such as acne, rosacea, seborrheic dermatitis, and perioral dermatitis has been controversially discussed for years. As part of a modern treatment approach, clinicians should provide patients with information on how their choice of diet might impact their dermatologic diagnosis and could potentially enhance therapeutic outcome. Recently, the concept of a gut-skin axis has gained momentum in the understanding of inflammatory dermatoses, with nutrition considered a contributing factor in this context. For example, gastrointestinal symptoms in rosacea patients may indicate a dysbiosis of the gut microbiome, treatment of which may also improve severity of the skin disease. New research efforts were recently made for acne patients addressing the clinical effects of omega-3 fatty acids and probiotics. In contrast, due to the limited data available, no comparable specific dietary recommendations can yet be made for seborrheic or perioral dermatitis. However, there are promising signs that clinical nutrition and dermatology will be more extensively interlinked in the future, both clinically and scientifically.


Acne Vulgaris , Dermatitis, Perioral , Facial Dermatoses , Rosacea , Skin Diseases , Acne Vulgaris/therapy , Humans , Rosacea/diagnosis , Rosacea/drug therapy , Skin , Skin Diseases/diagnosis , Skin Diseases/therapy
14.
J Eur Acad Dermatol Venereol ; 36(3): 380-390, 2022 Mar.
Article En | MEDLINE | ID: mdl-34779023

The plethora of pharmacologic treatments used for periorificial dermatitis (POD) makes clinical decision-making challenging. The objectives of this review were to assess the efficacy and safety of pharmacological interventions for POD in children and adults. The search was performed on 2 February 2021 and included seven databases and trial registries, with no date or language restrictions Study selection, data extraction and risk of bias assessments were performed independently and in duplicate by two authors, in accordance with a prespecified protocol. Meta-analyses were performed and reported in accordance with PRISMA guidelines. Where meta-analysis was not possible, a narrative synthesis was performed and reported in accordance with SWiM guidelines. The certainty of evidence was assessed using the Grading of Recommendation, Assessment, Development and Evaluation approach. Eleven studies representing 733 participants were included. Oral tetracycline may improve physician-reported severity of POD from day 20 onwards (low certainty evidence). Adverse effects may include abdominal discomfort, facial dryness and pruritus. Pimecrolimus cream may improve physician-reported severity slightly after 4 weeks of treatment (MD -0.49, 95% CI -1.02 to 0.04, n = 164, low certainty evidence). Adverse effects may include erythema, herpes simplex virus infection, burning and pruritus. Azelaic acid gel may result in no change in either physician- or patient-reported severity after 6 weeks of treatment. The evidence is very uncertain about the effect of praziquantel ointment on physician-reported severity and skin-related quality of life after 4 weeks of treatment. The evidence is also very uncertain about the effect of topical clindamycin/benzoyl peroxide on physician-reported severity. The body of evidence to inform treatment of POD currently consists of low and very low certainty evidence for important outcomes. Well-designed trials are needed to further investigate treatment options. Data are required for children and from low-middle income countries to improve external validity. Future trials should also include adequate post-treatment follow-up and standardized outcome measures.


Dermatitis, Perioral , Quality of Life , Adult , Child , Emollients/therapeutic use , Humans , Pruritus/drug therapy
15.
Acta Clin Croat ; 60(2): 276-281, 2021 Jun.
Article En | MEDLINE | ID: mdl-34744278

Oral cavity and perioral area are constantly exposed to a variety of antigens, including food and additives, which have a potential role in the development of different oral mucosal and perioral cutaneous diseases since they can cause hypersensitivity reactions. Oral and perioral diseases mainly include angioedema, burning mouth syndrome, cheilitis, gingivostomatitis, oral lichenoid reactions, and perioral dermatitis. Previous studies were focused on delayed-type oral allergies by performing patch testing but did not include tests for immediate-type allergic reactions. Therefore, the objective of this study was to determine common nutritive and additive allergens in the prevalent oral and perioral diseases by using skin prick tests. Our study evaluated 230 participants, i.e. 180 patients with oral/perioral diseases (angioedema, burning mouth syndrome, cheilitis, gingivostomatitis, oral lichenoid reactions, and perioral dermatitis), and 50 healthy control subjects. The results of skin prick tests showed that immediate-type allergic reactions to food and additives were mostly seen in patients with burning mouth syndrome (40%) and cheilitis (33.3%), whereas allergies were least frequently observed in perioral dermatitis (10%) and gingivostomatitis (20%). Fruits, mushrooms, and vegetables were the most frequent causes of nutritive allergies in oral and perioral diseases. The most commonly identified additive allergens were glutaraldehyde, citric acid, and sodium glutamate. Study results suggest the possible association with nutritive and additive allergies be considered in cases of persistent oral mucosal or perioral skin disease accompanied by respective medical history.


Angioedema , Burning Mouth Syndrome , Cheilitis , Dermatitis, Perioral , Food Hypersensitivity , Allergens , Burning Mouth Syndrome/diagnosis , Cheilitis/chemically induced , Cheilitis/diagnosis , Food Hypersensitivity/complications , Food Hypersensitivity/diagnosis , Humans
18.
Gac. méd. espirit ; 23(1): 35-45, ene.-abr. 2021. tab, graf
Article Es | LILACS | ID: biblio-1250004

RESUMEN Fundamento: El carcinoma basocelular periocular es una lesión tumoral que surge de las células basales de la epidermis y los folículos pilosos, con un alto potencial de destrucción local, pueden ser desfigurantes e invaden el tejido que los rodea dando lugar a deformidades o pérdida de la función del órgano afectado. En orden de aparición es más común en el párpado inferior, el canto medial, el párpado superior y el canto temporal. Objetivo: Describir los resultados de la aplicación del HeberFERON en una serie de casos con carcinoma basocelular periocular que acudieron a consulta de dermatología del Policlínico Centro, de enero de 2017 a diciembre del 2020. Metodología: Se realizó un estudio de serie de casos clínicos con carcinoma basocelular periocular que acudieron a la consulta de dermatología del Policlínico Centro. Se incluyeron 17 casos con diagnóstico clínico, dermatoscópico e histopatológico. Se realizó una evaluación inicial, durante y 16 semanas después del tratamiento; se administró 10.5 UI de HeberFERON 3 veces por semana perilesional e intradérmica hasta completar 9 dosis. Las variables principales fueron la respuesta al tratamiento y la presencia o no de eventos adversos. Resultados: Predominó el sexo masculino, el fototipocutáneo II, la localización en párpado inferior, el subtipo clínico nódulo ulcerativo y el histológico sólido, se logró respuesta completa en la mayoría de los pacientes. Como eventos adversos se presentaron dolor en el sitio de inyección, fiebre, mal estar general, edema y eritema perilesional. Conclusiones: La respuesta al tratamiento fue favorable en la mayoría de los pacientes tratados con HeberFERON.


ABSTRACT Background: Periocular basal cell carcinoma is a tumor lesion arising from the epidermis and hair follicles basal cells, with a high potential local destruction, can be disfiguring and invade the surrounding tissue leading to deformities or loss of function of the affected organ. In order of appearance it is most common in the lower eyelid, medial edge, upper eyelid and temporal edge. Objective: To describe the results of the application of HeberFERON in a case series with periocular basal cell carcinoma who attended dermatology appointment at the Policlínico Centro, from January 2017 to December 2020. Methodology: A series study of clinical cases with periocular basal cell carcinoma who attended the dermatology appointment at the Policlínico Centro was conducted. 17 cases with clinical, dermatoscopic and histopathological diagnosis were included. A baseline evaluation was conducted, during and 16 weeks after treatment; 10.5 IU of HeberFERON was administered 3 times a week perilesional and intradermally until completing 9 doses. The main variables were the treatment response and the presence or absence of adverse events. Results: Male sex, phototypocutaneous II, lower eyelid location, clinical subtype ulcerative nodule and solid histological subtype predominated, complete response was achieved in most patients. Adverse events were pain at the injection site, fever, general malaise, edema and perilesional erythema. Conclusions: Treatment response was favorable in most patients treated with HeberFERON.


Skin Neoplasms/therapy , Carcinoma, Basal Cell/therapy , Interferon alpha-2/therapeutic use , Dermatitis, Perioral/therapy
19.
J Cosmet Dermatol ; 20(12): 3839-3848, 2021 Dec.
Article En | MEDLINE | ID: mdl-33751778

BACKGROUND AND AIMS: Perioral dermatitis is a common cutaneous condition characterized by acneiform facial eruptions often with an eczematous appearance. A granulomatous subtype exists in addition to the classic variant. While topical corticosteroids have been largely implicated in this condition, its etiology is not completely understood. METHODS: Using the keywords "corticosteroids," "dermatology," "fusobacteria," "perioral dermatitis," and "periorificial dermatitis," we searched the databases PubMed, MEDLINE, and EMBASE to find the relevant literature. Only articles in English were chosen. The level of evidence was evaluated and selected according to the highest level working our way downwards using the Oxford Centre of Evidence-Based Medicine 2011 guidance. RESULTS: This systematic review found the strongest evidence to support topical corticosteroid misuse as the principal causative factor in the pathogenesis of perioral dermatitis. CONCLUSION: In terms of treatment, further research is required to robustly investigate promising treatment options including tetracyclines, topical metronidazole, topical azelaic acid, adapalene gel, and oral isotretinoin.


Dermatitis, Perioral , Dermatologic Agents , Anti-Bacterial Agents/therapeutic use , Dermatitis, Perioral/diagnosis , Dermatitis, Perioral/drug therapy , Dermatitis, Perioral/etiology , Dermatologic Agents/therapeutic use , Humans , Isotretinoin , Metronidazole/therapeutic use
20.
J Dermatol ; 48(3): 405-407, 2021 Mar.
Article En | MEDLINE | ID: mdl-33275294

Pediatric periorificial dermatitis is a papulopustular eruption found around the facial orifices in children. Although the treatment of the disease has been largely anecdotal and experience-based, studies have shown that topical calcineurin inhibitors, as well as other topical and oral antibiotics, such as metronidazole, can be effective treatment options. However, most of the studies with a sizable number of patients have been based on the Caucasian population. Herein, we evaluated the clinical efficacy of topical calcineurin inhibitors and topical/oral metronidazole in 24 Korean patients with pediatric periorificial dermatitis. The majority of the patients showed a complete response to treatment.


Dermatitis, Perioral , Exanthema , Administration, Topical , Anti-Bacterial Agents/therapeutic use , Calcineurin Inhibitors/therapeutic use , Child , Dermatitis, Perioral/diagnosis , Dermatitis, Perioral/drug therapy , Exanthema/drug therapy , Humans , Metronidazole
...